Entrada Therapeutics Inc. (TRDA)

AI Score

Unlock

11.49

-0.45 (-3.77%)

At close: Mar 03, 2025, 12:17 PM

No 1D chart data available

Bid	11.47
Market Cap	431.96M
Revenue (ttm)	198.23M
Net Income (ttm)	50.61M
EPS (ttm)	1.68
PE Ratio (ttm)	6.84
Forward PE	-4.34
Analyst	Buy

Ask	11.5
Volume	108,158
Avg. Volume (20D)	117,637
Open	11.95
Previous Close	11.94
Day's Range	11.39 - 11.79
52-Week Range	11.35 - 21.79
Beta	-0.17

About TRDA

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also eng...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 29, 2021

Employees 183

Stock Exchange NASDAQ

Ticker Symbol TRDA

Website https://www.entradatx.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for TRDA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 143.69% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Earnings Surprise

Entrada Therapeutics has released their quartely earnings on Feb 27, 2025:

Revenue of $37.4M exceeds estimates by $24.48M, with -10.63% YoY decline.

EPS of 0.03 exceeds estimates by 0.69, with 110.34% YoY growth.

Next Earnings Release

Entrada Therapeutics Inc. is scheduled to release its earnings on May 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

+11.26%

Entrada Therapeutics shares are trading higher. Th... Unlock content with Pro Subscription

News

3 days ago · zacks.com

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.66 per share. This compares to loss of $0.29 per share a yea...

1 week ago · seekingalpha.com

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Entrada Therapeutics addresses intracellular drug delivery challenges with its Endosomal Escape Vehicle platform, positioning itself uniquely in the biotech sector. Strong financials with $449.3 milli...

2 months ago · zacks.com

Best Momentum Stocks to Buy for December 30th

CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.

2 months ago · zacks.com

New Strong Buy Stocks for December 30th

CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.

2 months ago · zacks.com

Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why

Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it...